Tectonic Therapeutic (TECX) Other Non-Current Liabilities (2017 - 2023)
Tectonic Therapeutic (TECX) posted quarterly Other Non-Current Liabilities of $0.1 for Q4 2025, down 100.0% quarter-over-quarter from $371000.0 in Q4 2017.
Powered by 
Analysis
Tectonic Therapeutic (TECX) Other Non-Current Liabilities (2017 - 2023) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Other Non-Current Liabilities for 2 consecutive years, with $0.1 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $0.1; the TTM figure through Dec 2025 stood at $0.1 (changed N/A YoY), while the FY2025 annual figure was $0.1, changed N/A from the prior year.
- Other Non-Current Liabilities slipped to $0.1 in Q4 2025 per TECX's latest filing, from $371000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $0.1 in Q4 2025 and bottomed at $0.1 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Tectonic Therapeutic | 589.02 Mn | 589.02 Mn | - |